OncLive

Topline data from the phase 3 MagnetisMM-32 trial showed elranatamab improved PFS vs SOC in R/R multiple myeloma treated with at least 1 prior line of therapy that included an anti-CD38 monoclonal antibody and lenalidomide #mmsm #oncology Read more: www.onclive.com/view/elranat...

📰 The European Commission has approved T-DXd monotherapy for patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant treatment with a taxane and HER2-directed therapy. #bcsm #oncology Read more ➡️: www.onclive.com/view/t-dxd-g...

📈 After progression on a third-generation EGFR TKI, izalontamab brengitecan (iza-bren) improved median PFS to 11.1 months vs 5.7 months with platinum-based chemotherapy in phase 3 PANKU-Lung01. @myesmo.bsky.social #ESMO26 #lcsm #medtwitter #oncology 🔗 Read more: www.onclive.com/view/iza-bre...

In phase 3 SANOVO, savolitinib + osimertinib (Tagrisso) extended median PFS to 24.9 months vs 13.8 months with osimertinib alone in the overall study population. @myesmo.bsky.social #ESMO36 #lcsm 🔗 Read more: www.onclive.com/view/savolit...

📈 INCB161734 plus chemotherapy was tolerable and generated responses in patients with KRAS G12D–mutated advanced or metastatic PDAC, according to updated data from a phase 1 trial. @myesmo.bsky.social #ESMO2026 #pancsm #oncology Full story ➡️: www.onclive.com/view/incb161...

Extended follow-up data from DeLLphi-304 showed tarlatamab sustained survival benefits in patients with SCLC whose disease progressed during or after first-line platinum-based therapy #ESMO26 #lcsm #oncology Read more: www.onclive.com/view/extende...

Just in from #ESMO2026: Sac-TMT improved PFS and OS vs treatment of physician’s choice in previously treated, advanced/recurrent endometrial cancer; the agent is under @fda.gov priority review for this indication. @myesmo.bsky.social #gyncsm #oncology Full story ➡️: www.onclive.com/view/sac-tmt...

Treatment with risvutatug rezetecan yielded a statistically significant improvement in PFS for patients with relapsed/refractory osteosarcoma who received at least 2 prior lines of therapy #oncology Dive into the #ESMO26 data: www.onclive.com/view/ris-rez...

📰 A next-generation, whole genome sequencing version of the Oncodetect MRD test is now commercially available to detect cancer during and after treatment in patients with solid tumors. #oncology Full story ➡️: www.onclive.com/view/whole-g...

🚨BREAKING🚨: The @fda.gov has approved talazoparib in combination with enzalutamide for the treatment of adult patients with mAPM/S prostate cancer with HRR gene mutations, as detected by an FDA-authorized test. #pcsm #oncology Full story ➡️: www.onclive.com/view/fda-app...

📰 Trastuzumab pamirtecan delivered a statistically significant yet modest PFS improvement vs chemotherapy in patients with HR+, HER2-low metastatic breast cancer. #bcsm #oncology Full story ➡️: www.onclive.com/view/trastuz...

Niraparib plus dostarlimab and CRT (for cisplatin-eligible patients) or radiation alone (for cisplatin-ineligible patients) displayed efficacy but was hampered by toxicity concerns in locally advanced HNSCC #hncsm #oncology Dive into the RADIAN trial data: www.onclive.com/view/nirapar...

It's the #FiveUnder5 roundup of #oncology videos, w/ insights from: 🌟 Frank A. Sinicrope, MD @mayocliniccancer.bsky.social 🌟 Andrea Cercek, MD @mskcancercenter.bsky.social 🌟 Julia T. Warren, MD, PhD 🌟 Ashley Margol, MD, MS 🌟 Paul E. Oberstein, MD www.onclive.com/view/five-un...

📣 Presidential Symposium Spotlight 📣: Head-to-head vs sotorasib or adagrasib, divarasib improved PFS and OS in previously treated KRAS G12C+ NSCLC in the phase 3 Krascendo 1 trial. Full @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/divaras... #lcsm #oncology @mdanderson.bsky.social

✨ Presidential Symposium Spotlight ✨: Sonesitatug vedotin doubled median OS vs investigator’s choice in 3L+ CLDN18.2+ gastroesophageal carcinoma in the phase 3 CLARITY-Gastric01 trial, though PFS fell short of significance. Full @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/clarity...

✨ @myesmo.bsky.social #ESMO26 Presidential Symposium Spotlight✨: Head-to-head vs durvalumab + chemo, ivonescimab + gemcitabine/cisplatin improved OS, PFS, and ORR in first-line advanced BTC in the phase 3 HARMONi-GI1 trial. Full data: www.onclive.com/view/ivonesc... #oncology

📣 A chemo-free option after osimertinib? In the phase 3 SAFFRON trial, osimertinib + savolitinib improved PFS and OS vs platinum/pemetrexed in EGFR+ NSCLC with MET overexpression/amplification. Full @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/saffron... #oncology #lcsm

Such a fantastic interview with Dr Daniel Heng, Arthur J.E. Child Comprehensive Cancer Centre, on the final LITESPARK-011 analysis in advanced RCC @myesmo.bsky.social #ESMO26 And we also got a photo bomb from the one and only @drchoueiri.bsky.social @drchoueiri.bsky.social Check onclive.com!

INTerpath-001: Intismeran autogene + pembrolizumab reduced the risk of recurrence or death by 42% vs pembrolizumab alone in melanoma. The combination also lowered the risk of distant metastasis or death by 38%. @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/adjuvan...

A standing ovation: Tarlatamab + durvalumab as frontline maintenance in ES-SCLC, phase 3 DeLLphi-305. Data presented at the @myesmo.bsky.social #ESMO26 Presidential Symposium support a new SOC. #lcsm #medtwitter #oncology @danafarber.bsky.social www.onclive.com/view/dellphi...

📈 Tovecimig plus paclitaxel improved ORR compared with paclitaxel alone in previously treated advanced biliary tract cancer in the phase 2/3 COMPANION-002 trial. @myesmo.bsky.social #ESMO2026 #oncology Full story ➡️: www.onclive.com/view/tovecim...

Adding pembrolizumab to adjuvant radiation did not improve 3-year RFS in newly diagnosed, early-stage, high-intermediate–risk, dMMR endometrial cancer #gynsm #oncology #ESMO26 Read more: www.onclive.com/view/nrg-gy0...

Dato-DXd improved CNS PFS and IC response vs investigator's choice of chemotherapy in locally recurrent inoperable or metastatic TNBC and baseline brain metastases for whom IO was not an option #ESMO26 #bcsm #oncology Dive into the TROPION-Breast02 subgroup data: www.onclive.com/view/first-l...

New phase 1 data presented at @myesmo.bsky.social #ESMO26 show a 48% response rate with INCB123667 plus bevacizumab in heavily pretreated, cyclin E1–overexpressing platinum-resistant ovarian cancer. Read more: www.onclive.com/view/incb123... #gyncsm #oncology

📈 Neoadjuvant T-DXd followed by THP elicited faster and deeper tumor responses on MRI than ddAC-THP in HER2+ early breast cancer, but MRI response did not reliably predict pCR in a DESTINY-Breast11 analysis. @myesmo.bsky.social #ESMO2026 #bcsm #oncology Read more: www.onclive.com/view/t-dxd-f...

🧬 In phase 1 CATALINA-1, ixotatug vedotin achieved a 45.5% response rate in 11 patients with heavily pretreated germ cell tumors. Half of those previously treated with HDCT/ASCT responded. Read more: www.onclive.com/view/ixotatu... @myesmo.bsky.social #ESMO26 @mskcancercenter.bsky.social

📈 Significant PFS improvements were shown with iza-bren vs chemotherapy in pretreated HR+/HER2– advanced breast cancer, according to new data from the phase 3 PANKU-Breast01 trial Read more here ➡️: www.onclive.com/view/panku-b... #bcsm #oncology #ESMO26 @myesmo.bsky.social

Exploratory data from KEYNOTE-B15 showed enfortumab vedotin/pembrolizumab improved ctDNA clearance in cisplatin-eligible MIBC #blcsm #oncology Check out the findings presented at #ESMO26: www.onclive.com/view/keynote...

At @myesmo.bsky.social #ESMO26, interim TROPHY-U-01 findings shed light on the potential of sacituzumab govitecan, enfortumab vedotin, and zimberelimab. Read more: www.onclive.com/view/sacituz... #oncology

Perioperative pembrolizumab plus neoadjuvant chemo did not improve EFS vs placebo plus chemo in pts w/ cisplatin-eligible MIBC undergoing radical cystectomy with pelvic lymph node dissection, according to KEYNOTE-866. @myesmo.bsky.social #ESMO2026 #blcsm #oncology www.onclive.com/view/pembrol...

Ad hoc data from KEYNOTE-905/EV-303 showed consistent efficacy contributions for both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC #blcsm #oncology Read more from #ESMO26: www.onclive.com/view/ad-hoc-...

Subgroup analyses from RASolute 302 showed daraxonrasib maintained its OS benefit across RAS mutation subtypes #pancsm #oncology Dive into the latest pancreatic cancer data to emerge from the study: www.onclive.com/view/daraxon...

Adjuvant giredestrant sustained physical functioning, role functioning, and HRQOL and was associated with sustained low AE bother vs SOC in ER+, HER2– early breast cancer, according to PROs from lidERA Breast Cancer. @myesmo.bsky.social #ESMO2026 #bcsm #oncology www.onclive.com/view/adjuvan...

The addition of perioperative nivolumab to neoadjuvant chemo did not yield a statistically significant improvement in pCR rate or EFS vs neoadjuvant chemo alone in muscle-invasive bladder cancer #blcsm #oncology Dive into the #ESMO26 data here: www.onclive.com/view/periope...

Thank you to Rahul Winayak, MD, of @cityofhope.bsky.social for sharing insights from research on novel target expressions in renal cell carcinoma, being presented at #ESMO26

Big thanks to DarrenFeldman, MD, of @mskcancercenter.bsky.social for stopping by to discuss data for ixotatug vedotin in germ cell tumors being presented at #ESMO26!

Just in: Teclistamab monotherapy is now approved in the EU for relapsed/refractory multiple myeloma following at least 1 prior line of therapy #mmsm #oncology Read more: www.onclive.com/view/teclist...

No matter which character you choose, OncLive is going to cover all of ESMO❗ As the conference begins today, we are ready to go with several team members on the ground in Madrid 🇪🇸 Check our site for real-time coverage: www.onclive.com/conference/e... @myesmo.bsky.social #ESMO26 #oncology

Poll Results: Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at #ESMO2026. @myesmo.bsky.social #lcsm #oncology Full recap ➡️: www.onclive.com/view/polls-r...

Poll Recap: Readers share their opinions on some of the most talked-about gynecologic cancer abstracts and topics they’re looking forward to seeing at #ESMO2026. @myesmo.bsky.social #gyncsm #oncology Full story ➡️: www.onclive.com/view/poll-re...

WATCH: P. Leia Nghiemphu, MD, of @uclahealth.org, discusses the significance of the inclusion of brigatinib in the NCCN Clinical Practice Guidelines in Oncology for NF2-related schwannomatosis. #oncology Full video: www.onclive.com/view/dr-nghi...

With multiple therapies available for HER2+ mCRC, the challenge is finding eligible patients early in their disease course and choosing the optimal order of therapy. @weillcornell.bsky.social #crcsm #oncology www.onclive.com/view/her2-mc...

🚨BREAKING🚨: The @fda.gov has granted traditional approval to pembrolizumab for patients with unresectable or metastatic TMB-H solid tumors who have progressed following prior treatment and have no satisfactory alternative treatment options. #oncology www.onclive.com/view/fda-gra...

Phase 1 data showed the PI3Kδ inhibitor roginolisib demonstrated preliminary antitumor activity and a safety profile that supports further evaluation in patients with advanced or metastatic cancers, including metastatic uveal melanoma #melsm #oncology www.onclive.com/view/roginol...

WATCH 📺: Paul E. Oberstein, MD, discusses the rationale for investigating the anti-PD-1/IL-15 fusion protein SAR445877 in microsatellite-stable colorectal cancer. #crcsm #oncology Full video ➡️: www.onclive.com/view/dr-ober...

The EC has approved perioperative enfortumab vedotin plus pembrolizumab for the treatment of resectable MIBC, irrespective of cisplatin eligibility #blcsm #oncology www.onclive.com/view/pembrol...

Thoracic oncologists weigh TROP2 ADCs for EGFRm NSCLC. @elaineshummd.bsky.social @ddoroshow.bsky.social @fionnualacrowley.bsky.social @massgenbrigham.bsky.social @mskcancercenter.bsky.social @weillcornell.bsky.social #lcsm #oncology www.onclive.com/view/tolerab...

📺 WATCH: Frank Sinicrope, MD, of @mayocliniccancer.bsky.social, previews 2 colorectal cancer studies to watch at the 2026 ESMO Congress, including adjuvant treatment intensification and the AZUR-1 trial. @myesmo.bsky.social #ESMO2026 #crcsm #oncology Full video ➡️: www.onclive.com/view/dr-sini...

China's CDE has granted breakthrough therapy designation to lisaftoclax plus acalabrutinib for previously untreated CLL and SLL #leusm #oncology Read more: www.onclive.com/view/lisafto...

What does the @fda.gov accelerated approval of dostarlimab mean for the management of dMMR/MSI-H locally advanced rectal cancer? Andrea Cercek, MD, of @mskcancercenter.bsky.social breaks down the significance and the findings from AZUR-1 #crcsm #oncology Read more: www.onclive.com/view/fda-app...